Almac Group has created a separate division called Almac Discovery, focussed exclusively on the discovery and development of novel approaches to the treatment of cancer and associated conditions, with the goal of developing a biomarker or diagnostic with each potential new drug. According to the company, projects will generally be taken to clinical proof of concept (or earlier) before out-licensing or partnering for further development. Almac Discovery is looking to build its internal pipeline through partnerships and in-licensing.
   
Sir Allen McClay, chairman and founder of the Almac Group, said, “The launch of Almac Discovery is an exciting opportunity to drive forward  a dedicated effort toward the development of novel therapeutics for the treatment of cancer. Almac Discovery provides us the opportunity to build upon the strong research base already established within the  academic community within Northern Ireland in the basic biology of  cancer, and make a real and lasting contribution towards the  advancement of human health.”